Harnessing regulatory T cells for transplant tolerance in the clinic through mTOR inhibition: Myth or reality?

Current Opinion in Organ Transplantation

Volumn 16, Issue 6, 2011, Pages 606-613

  Zuber, Julien ^a,b   Hermine, Olivier ^a,b   Chatenoud, Lucienne ^a,b   Legendre, Christophe ^a,b  

^a UNIVERSITÉ PARIS DESCARTES   (France)

^b HÔPITAL NECKER ENFANTS MALADES   (France)

Author keywords

immune tolerance; mTOR inhibitor; paradoxical inflammatory effects; regulatory T cells

Indexed keywords

MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; PROTEIN KINASE B; STAT5 PROTEIN; TRANSCRIPTION FACTOR FOXP3;

IMMUNE SYSTEM; IN VITRO STUDY; IN VIVO STUDY; PROTEIN EXPRESSION; REVIEW; T LYMPHOCYTE;

ANIMALS; GRAFT REJECTION; GRAFT SURVIVAL; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MOLECULAR TARGETED THERAPY; ORGAN TRANSPLANTATION; PROTEIN KINASE INHIBITORS; SIGNAL TRANSDUCTION; T-LYMPHOCYTES, REGULATORY; TOR SERINE-THREONINE KINASES; TRANSPLANTATION TOLERANCE; TREATMENT OUTCOME;

EID: 81255185336     PISSN: 10872418     EISSN: 15317013     Source Type: Journal    
DOI: 10.1097/MOT.0b013e32834c237a     Document Type: Review

References (77)

1. Nepom GT, St Clair EW, Turka LA. Challenges in the pursuit of immune tolerance. Immunol Rev 2011; 241:49-62.
2. Waldmann H. Tolerance: an overview and perspectives. Nat Rev Nephrol 2010; 6:569-576.
3. + regulatory T cells. Nat Rev Immunol 2011; 11:119-130.
4. + regulatory T cells: control of FOXP3 expression by pharmacological agents. Trends Pharmacol Sci 2011; 32:158-166.
5. Gao W, Lu Y, El Essawy B, et al. Contrasting effects of cyclosporine and rapamycin in de novo generation of alloantigen-specific regulatory T cells. Am J Transplant 2007; 7:1722-1732. (Pubitemid 46905432)
6. Knechtle SJ, Pirsch JD, H Fechner J, et al. Campath-1H induction plus rapamycin monotherapy for renal transplantation: results of a pilot study. Am J Transplant 2003; 3:722-730. (Pubitemid 36745245)
7. Powell JD, Delgoffe GM. The mammalian target of rapamycin: linking T cell differentiation, function, and metabolism. Immunity 2010; 33:301-311.
8. + regulatory T cells. J Immunol 2004; 172:5287-5296. (Pubitemid 38542026)
9. + T regulatory cells. Blood 2007; 109:2014-2022. (Pubitemid 46348201)
10. Walsh PT, Buckler JL, Zhang J, et al. PTEN inhibits IL-2 receptor-mediated expansion of CD4+ CD25+ Tregs. J Clin Invest 2006; 116:2521-2531. (Pubitemid 44330151)
11. Patterson SJ, Han JM, Garcia R, et al. Cutting edge: PHLPP regulates the development, function, and molecular signaling pathways of regulatory T cells. J Immunol 2011; 186:5533-5537.
12. Kohlhaas S, Garden OA, Scudamore C, et al. Cutting edge: the Foxp3 target miR-155 contributes to the development of regulatory T cells. J Immunol 2009; 182:2578-2582.
13. Locke NR, Patterson SJ, Hamilton MJ, et al. SHIP regulates the reciprocal development of T regulatory and Th17 cells. J Immunol 2009; 183:975-983.
14. Procaccini C, De Rosa V, Galgani M, et al. An oscillatory switch in Mtor kinase activity sets regulatory T cell responsiveness. Immunity 2010; 33:929-941.
15. Sauer S, Bruno L, Hertweck A, et al. T cell receptor signaling controls Foxp3 expression via PI3K, Akt, and mTOR. Proc Natl Acad Sci U S A 2008; 105:7797-7802. (Pubitemid 351872718)
16. + cells. J Exp Med 2008; 205:565-574. (Pubitemid 351439304)
17. Delgoffe GM, Kole TP, Zheng Y, et al. The mTOR kinase differentially regulates effector and regulatory T cell lineage commitment. Immunity 2009; 30:832-844.
18. Ouyang W, Li MO. Foxo: in command of T lymphocyte homeostasis and tolerance. Trends Immunol 2011; 32:26-33.
19. Yu A, Zhu L, Altman NH, et al. A low interleukin-2 receptor signaling threshold supports the development and homeostasis of T regulatory cells. Immunity 2009; 30:204-217.
20. Basu S, Golovina T, Mikheeva T, et al. Cutting edge: Foxp3-mediated induction of pim 2 allows human T regulatory cells to preferentially expand in rapamycin. J Immunol 2008; 180:5794-5798.
21. Fox CJ, Hammerman PS, Thompson CB. The Pim kinases control rapamycinresistant T cell survival and activation. J Exp Med 2005; 201:259-266. (Pubitemid 40189435)
22. Thomson AW, Turnquist HR, Raimondi G. Immunoregulatory functions of mTOR inhibition. Nat Rev Immunol 2009; 9:324-337.
23. + regulatory T cells is driven by the c-Rel enhanceosome. Immunity 2009; 31:932-940.
24. Wan YY, Chi H, Xie M, et al. The kinase TAK1 integrates antigen and cytokine receptor signaling for T cell development, survival and function. Nat Immunol 2006; 7:851-858. (Pubitemid 44084092)
25. Zheng Y, Josefowicz S, Chaudhry A, et al. Role of conserved noncoding DNA elements in the Foxp3 gene in regulatory T-cell fate. Nature 2010; 463:808-812.
26. Lio CW, Hsieh CS. A two-step process for thymic regulatory T cell development. Immunity 2008; 28:100-111.
27. + regulatory T cells of both healthy subjects and type 1 diabetic patients. J Immunol 2006; 177:8338-8347. (Pubitemid 44893795)
28. + regulatory T cells. Blood 2006; 107:1018-1023. (Pubitemid 43156300)
29. + cells in vitro. Am J Transplant 2005; 5:454-464. (Pubitemid 40313336)
30. + regulatory T cells. Blood 2005; 105:4743-4748. (Pubitemid 40807298)
31. Strauss L, Czystowska M, Szajnik M, et al. Differential responses of human regulatory T cells (Treg) and effector T cells to rapamycin. PLoS One 2009; 4:e5994.
32. Teachey DT,ObzutDA, AxsomK, et al.Rapamycin improves lymphoproliferative disease in murine autoimmune lymphoproliferative syndrome (ALPS). Blood 2006; 108:1965-1971. (Pubitemid 44395007)
33. Teachey DT, Greiner R, Seif A, et al. Treatment with sirolimus results in complete responses in patients with autoimmune lymphoproliferative syndrome. Br J Haematol 2009; 145:101-106.
34. + regulatory T cell recruitment in human renal allograft infiltrates. J Immunol 2007; 79:4901-4909.
35. Brouard S, Puig-Pey I, Lozano JJ, et al. Comparative transcriptional and phenotypic peripheral blood analysis of kidney recipients under cyclosporine A or sirolimus monotherapy. Am J Transplant 2010; 10:2604-2614.
36. Noris M, Casiraghi F, Todeschini M, et al. Regulatory T cells and T cell depletion: role of immunosuppressive drugs. J Am Soc Nephrol 2007; 18:1007-1018. (Pubitemid 46434518)
37. Bindl L, Torgerson T, Perroni L, et al. Successful use of the new immunesuppressor sirolimus in IPEX (immune dysregulation, polyendocrinopathy, enteropathy, X-linked syndrome). J Pediatr 2005; 147:256-259. (Pubitemid 41207844)
38. Yong PL, Russo P, Sullivan KE. Use of sirolimus in IPEX and IPEX-like children. J Clin Immunol 2008; 28:581-587.
39. Safinia N, Sagoo P, Lechler R, et al. Adoptive regulatory T cell therapy: challenges in clinical transplantation. Curr Opin Organ Transplant 2010; 15:427-434.
40. Li Y, Li XC, Zheng XX, et al. Blocking both signal 1 and signal 2 of T-cell activation prevents apoptosis of alloreactive T cells and induction of peripheral allograft tolerance. Nat Med 1999; 5:1298-1302. (Pubitemid 29535608)
41. Zheng XX, Sanchez-Fueyo A, Sho M, et al. Favorably tipping the balance between cytopathic and regulatory T cells to create transplantation tolerance. Immunity 2003; 19:503-514. (Pubitemid 37311432)
42. Flechner SM, Friend PJ, Brockmann J, et al. Alemtuzumab induction and sirolimus plus mycophenolate mofetil maintenance for CNI and steroid-free kidney transplant immunosuppression. Am J Transplant 2005; 5:3009-3014. (Pubitemid 43923964)
43. Knechtle SJ, Pascual J, Bloom DD, et al. Early and limited use of tacrolimus to avoid rejection in an alemtuzumab and sirolimus regimen for kidney transplantation: clinical results and immune monitoring. Am J Transplant 2009; 9:1087-1098.
44. Ruggenenti P, Perico N, Gotti E, et al. Sirolimus versus cyclosporine therapy increases circulating regulatory T cells, but does not protect renal transplant patients given alemtuzumab induction from chronic allograft injury. Transplantation 2007; 84:956-964. (Pubitemid 350287376)
45. Park SG, Mathur R, Long M, et al. T regulatory cells maintain intestinal homeostasis by suppressing gammadelta T cells. Immunity 2010; 33:791-803.
46. Patton DT, Wilson MD, Rowan WC, et al. The PI3K p110delta regulates expression of CD38 on regulatory T cells. PLoS One 2011; 6:e17359.
47. Chaudhry A, Rudra D, Treuting P, et al. CD4+ regulatory T cells control TH17 responses in a Stat3-dependent manner. Science 2009; 326:986-991.
48. Wander SA, Hennessy BT, Slingerland JM. Next-generation mTOR inhibitors in clinical oncology: how pathway complexity informs therapeutic strategy. J Clin Invest 2011; 121:1231-1241.
49. Hippen KL, Merkel SC, Schirm DK, et al. Massive ex vivo expansion of human natural regulatory T cells (Tregs) with minimal loss of in vivo functional activity. Sci Transl Med 2011; 3:83ra41.
50. Ferrer IR, Araki K, Ford ML. Paradoxical aspects of rapamycin immunobiology in transplantation. Am J Transplant 2011; 11:654-659.
51. Saemann MD, Haidinger M, Hecking M, et al. The multifunctional role of mTOR in innate immunity: implications for transplant immunity. Am J Transplant 2009; 9:2655-2661.
52. + T cell responses. J Immunol 2010; 185:2004-2008.
53. Amir AL, DOrsogna LJ, Roelen DL, et al. Allo-HLA reactivity of virus-specific memory T cells is common. Blood 2010; 115:3146-3157.
54. + T cell memory and tumor immunity. Immunity 2011; 34:541-553.
55. Minamimura K, Sato K, Yagita H, et al. Strategies to induce marked prolongation of secondary skin allograft survival in alloantigen-primed mice. Am J Transplant 2008; 8:761-772. (Pubitemid 351347753)
56. Wu Z, Bensinger SJ, Zhang J, et al. Homeostatic proliferation is a barrier to transplantation tolerance. Nat Med 2004; 10:87-92. (Pubitemid 38524703)
57. Weichhart T, Haidinger M, Katholnig K, et al. Inhibition of mTOR blocks the anti inflammatory effects of glucocorticoids in myeloid immune cells. Blood 2011; 117:4273-4283.
58. Haidinger M, Poglitsch M, Geyeregger R, et al. A versatile role of mammalian target of rapamycin in human dendritic cell function and differentiation. J Immunol 2010; 185:3919-3931.
59. Dominguez-Villar M, Baecher-Allan CM, Hafler DA. Identification of T helper type 1-like, Foxp3(+) regulatory T cells in human autoimmune disease. Nat Med 2011; 17:673-675.
60. Benson MJ, Pino-Lagos K, Rosemblatt M, et al. All-trans retinoic acid mediates enhanced T reg cell growth, differentiation, and gut homing in the face of high levels of co-stimulation. J Exp Med 2007; 204:1765-1774. (Pubitemid 47236315)
61. Golovina TN, Mikheeva T, Brusko TM, et al. Retinoic acid and rapamycin differentially affect and synergistically promote the ex vivo expansion of natural human T regulatory cells. PLoS One 2011; 6:e15868.
62. Lal G, Bromberg JS. Epigenetic mechanisms of regulation of Foxp3 expression. Blood 2009; 114:3727-3735.
63. Lu L, Zhou X, Wang J, et al. Characterization of protective human CD4CD25 FOXP3 regulatory T cells generated with IL-2, TGF-beta and retinoic acid. PLoS One 2010; 5:e15150.
64. Fayyad-Kazan H, Rouas R, Merimi M, et al. Valproate treatment of human cord blood CD4-positive effector T cells confers on them the molecular profile (microRNA signature and FOXP3 expression) of natural regulatory CD4- positive cells through inhibition of histone deacetylase. J Biol Chem 2010; 285:20481-20491.
65. Tao R, de Zoeten EF, Ozkaynak E, et al. Deacetylase inhibition promotes the generation and function of regulatory T cells. Nat Med 2007; 13:1299-1307. (Pubitemid 350073591)
66. Xiao Y, Li B, Zhou Z, et al. Histone acetyltransferase mediated regulation of FOXP3 acetylation and Treg function. Curr Opin Immunol 2010; 22:583-591.
67. Zanin-Zhorov A, Ding Y, Kumari S, et al. Protein kinase C-theta mediates negative feedback on regulatory T cell function. Science 2010; 328:372-376.
68. Lee K, Gudapati P, Dragovic S, et al. Mammalian target of rapamycin protein complex 2 regulates differentiation of Th1 and Th2 cell subsets via distinct signaling pathways. Immunity 2010; 32:743-753.
69. Liu G, Yang K, Burns S, et al. The S1P(1)-mTOR axis directs the reciprocal differentiation of T(H)1 and T(reg) cells. Nat Immunol 2010; 11:1047-1056.
70. Cheng G, Yu A, Malek TR. T-cell tolerance and the multifunctional role of IL-2R signaling in T-regulatory cells. Immunol Rev 2011; 241:63-76.
71. Lu LF, Thai TH, Calado DP, et al. Foxp3-dependent microRNA155 confers competitive fitness to regulatory T cells by targeting SOCS1 protein. Immunity 2009; 30:80-91.
72. + regulatory T cells. Nat Med 2005; 11:1238-1243. (Pubitemid 43093672)
73. Das BB, Madsen JC. Yale University School of Medicine: 2007 student thesis abstracts. Yale J Biol Med 2007; 80:1-38.
74. Kim JS, Lee JI, Shin JY, et al. Bortezomib can suppress activation of rapamycin- resistant memory T cells without affecting regulatory T-cell viability in nonhuman primates. Transplantation 2009; 88:1349-1359.
75. + effector memory T cells based on CD2 expression. Am J Transplant 2011; 11:22-33.
76. You S, Chatenoud L. New generation CD3 monoclonal antibodies: are we ready to have them back in clinical transplantation? Curr Opin Organ Transplant 2010; 15:720-724.
77. Rudensky AY, Gavin M, Zheng Y. FOXP3 and NFAT: partners in tolerance. Cell 2006; 126:253-256. (Pubitemid 44092973)